载脂蛋白B是外周动脉疾病和冠心病的主要因果脂蛋白危险因素
本研究利用大规模遗传关联数据,采用孟德尔随机化贝叶斯模型平均框架,对外周动脉疾病(PAD)和冠心病(CAD)的脂蛋白相关性状进行因果排序。结果发现载脂蛋白B(ApoB)是两者最可能的因果脂蛋白危险因素,但ApoB降低对外周动脉疾病和冠心病的影响强度不同,且不同脂蛋白亚组分与两种疾病关联存在差异。
要点
- ApoB是PAD和CAD最可能的因果脂蛋白危险因素。
- ApoB降低对CAD的预测效应强于PAD。
- 极小型VLDL颗粒浓度与PAD风险关联最可能,大型LDL颗粒浓度与CAD风险关联最可能。
核心结论
- ApoB被优先确定为PAD和CAD风险的主要因果脂蛋白组分。
- ApoB降低药物靶点和含ApoB脂蛋白亚组分与动脉粥样硬化性心血管疾病关联多样,不同亚组分相关基因提示PAD和CAD发病机制中脂蛋白作用可能存在差异。
研究设计与样本
- 利用循环脂蛋白相关性状的全基因组关联研究汇总统计量,在孟德尔随机化贝叶斯模型平均框架中优先排序PAD和CAD最可能的因果主要脂蛋白及亚组分危险因素。
- 使用代理降脂药物靶点的基因区域,通过孟德尔随机化估计ApoB降低对PAD风险的影响。
- 通过转录组关联研究识别与优先脂蛋白亚组分相关的基因。
主要发现
- ApoB被确定为PAD(边际包含概率0.86;P=0.003)和CAD(边际包含概率0.92;P=0.005)最可能的因果脂蛋白相关危险因素。
- ApoB降低药物遗传代理与PAD风险降低相关(每降低1-SD ApoB的比值比0.87 [95% CI, 0.84-0.91];P=9×10-10),也与CAD风险降低相关(比值比0.66 [95% CI, 0.63-0.69];P=4×10-73),ApoB降低对CAD的预测效应更强(效应比3.09 [95% CI, 2.29-4.60];P<1×10-6)。
- 极小型极低密度脂蛋白颗粒浓度是与PAD风险关联最可能的亚组分(边际包含概率0.91;P=2.3×10-4),而大型低密度脂蛋白颗粒浓度是与CAD风险关联最可能的亚组分(边际包含概率0.95;P=0.011)。
- 与极小型极低密度脂蛋白颗粒和大型低密度脂蛋白颗粒浓度相关的基因包括经典ApoB通路组分,但基因特异性效应可变。
- 脂蛋白(a)与PAD风险增加相关,且独立于ApoB(比值比1.04 [95% CI, 1.03-1.04];P=1.0×10-33)。
临床怎么用
- ApoB可作为PAD和CAD风险评估及降脂治疗监测的统一脂蛋白指标。
- 降低ApoB对CAD的预期获益大于PAD,但PAD患者仍可从ApoB降低中获益。
- 脂蛋白(a)升高是PAD的独立危险因素,在PAD风险评估中可考虑检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lipoprotein-related traits have been consistently identified as risk factors for atherosclerotic cardiovascular disease, largely on the basis of studies of coronary artery disease (CAD). The relative contributions of specific lipoproteins to the risk of peripheral artery disease (PAD) have not been well defined. We leveraged large-scale genetic association data to investigate the effects of circulating lipoprotein-related traits on PAD risk. METHODS: Genome-wide association study summary statistics for circulating lipoprotein-related traits were used in the mendelian randomization bayesian model averaging framework to prioritize the most likely causal major lipoprotein and subfraction risk factors for PAD and CAD. Mendelian randomization was used to estimate the effect of apolipoprotein B (ApoB) lowering on PAD risk using gene regions proxying lipid-lowering drug targets. Genes relevant to prioritized lipoprotein subfractions were identified with transcriptome-wide association studies. RESULTS: ApoB was identified as the most likely causal lipoprotein-related risk factor for both PAD (marginal inclusion probability, 0.86; P=0.003) and CAD (marginal inclusion probability, 0.92; P=0.005). Genetic proxies for ApoB-lowering medications were associated with reduced risk of both PAD (odds ratio,0.87 per 1-SD decrease in ApoB [95% CI, 0.84-0.91]; P=9×10-10) and CAD (odds ratio,0.66 [95% CI, 0.63-0.69]; P=4×10-73), with a stronger predicted effect of ApoB lowering on CAD (ratio of effects, 3.09 [95% CI, 2.29-4.60]; P<1×10-6). Extra-small very-low-density lipoprotein particle concentration was identified as the most likely subfraction associated with PAD risk (marginal inclusion probability, 0.91; P=2.3×10-4), whereas large low-density lipoprotein particle concentration was the most likely subfraction associated with CAD risk (marginal inclusion probability, 0.95; P=0.011). Genes associated with extra-small very-low-density lipoprotein particle and large low-density lipoprotein particle concentration included canonical ApoB pathway components, although gene-specific effects were variable. Lipoprotein(a) was associated with increased risk of PAD independently of ApoB (odds ratio, 1.04 [95% CI, 1.03-1.04]; P=1.0×10-33). CONCLUSIONS: ApoB was prioritized as the major lipoprotein fraction causally responsible for both PAD and CAD risk. However, ApoB-lowering drug targets and ApoB-containing lipoprotein subfractions had diverse associations with atherosclerotic cardiovascular disease, and distinct subfraction-associated genes suggest possible differences in the role of lipoproteins in the pathogenesis of PAD and CAD.
引用
- Levin MG, Zuber V, Walker VM, et al. Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease. Circulation. 2021. PMID: 34139859. doi:10.1161/CIRCULATIONAHA.121.053797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。